海辰药业(300584) - 2023 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2023 was ¥517,832,192, a decrease of 1.64% compared to ¥526,465,340 in 2022[19] - The net profit attributable to shareholders for 2023 was ¥36,315,554, an increase of 11.92% from ¥32,448,867 in 2022[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,965,334, reflecting a 17.51% increase from ¥31,458,351 in 2022[19] - The net cash flow from operating activities improved significantly to ¥23,932,692, a 511.26% increase from a negative cash flow of ¥5,819,338 in 2022[19] - The total assets at the end of 2023 were ¥1,408,864,380.40, an increase of 8.88% from ¥1,293,945,410.29 at the end of 2022[19] - The net assets attributable to shareholders increased to ¥987,496,138.22, up 3.89% from ¥950,566,396.43 at the end of 2022[19] - The basic earnings per share for 2023 were ¥0.3026, an increase of 11.91% compared to ¥0.2704 in 2022[19] - The diluted earnings per share also stood at ¥0.3026, reflecting the same growth of 11.91% from the previous year[19] - The weighted average return on equity for 2023 was 3.75%, an increase from 3.42% in 2022[19] Market and Product Development - The company plans to continue focusing on new product development and market expansion strategies to enhance future growth prospects[3] - The company has launched multiple high-quality products with significant market shares, including an injectable form of Torasemide, which achieved a market share of approximately 80% in its category[35] - The injectable form of Labetalol is a unique first-to-market product with two core patents, recommended in multiple clinical guidelines, and has been continuously included in the National Medical Insurance Directory[38] - Rivaroxaban tablets, the first oral direct Factor Xa inhibitor, have been included in several authoritative treatment guidelines and won bids in the national centralized procurement, enhancing the product's market competitiveness[39] - Tigecycline injection, known as a "super antibiotic," is included in the National Medical Insurance Directory and has been selected in the national centralized procurement, which is expected to increase its market share[40] - The injectable form of Torasemide is a new generation diuretic with strong and rapid effects, but its sales have been impacted by low-priced competitors in certain markets[41] - The company has established a comprehensive procurement, production, and sales system to ensure product quality and stable supply[42] - The company employs a sales model that emphasizes refined management and tracking of sales processes in hospitals to enhance market penetration[43] Research and Development - The company has established a comprehensive R&D system with over 60 dedicated personnel, focusing on drug development and innovation[45] - The company is actively involved in national and provincial-level technology projects, enhancing its R&D capabilities through collaboration with NMS Group, a leading European oncology drug research institution[46] - The company has submitted 3 invention patent applications and received authorization for 1 invention patent during the reporting period[57] - A total of 4 products (6 specifications) were approved for market by the National Medical Products Administration, including 4 generic products and 2 consistency evaluation products[57] - The company has 17 key research projects underway, with plans to submit several generic drug registration applications in 2024[60][61] Financial Management and Cost Control - The company achieved a production cost control and improved inventory efficiency, contributing to overall cost reduction[62] - The company reported a decrease in raw material costs by 29.79% to ¥43,526,694.72, contributing to improved margins[75] - The total sales expenses decreased by 10.09% to ¥241,595,638.54, reflecting cost control measures[80] - The company experienced a significant increase in depreciation expenses, which fell by 37.42% to ¥9,968,322.52[75] - The company’s investment activities generated a net cash outflow of ¥137,266,120.14, a decrease of 571.42% year-on-year[84] Corporate Governance - The company has established a comprehensive governance structure to ensure effective decision-making and protect shareholder rights[112] - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[115] - The board of directors includes a strategic committee, audit committee, nomination committee, and compensation and assessment committee to enhance governance[113] - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, linking their compensation to company performance and individual achievements[114] - The company has a complete research, production, and sales system, ensuring independent business operations[115] Environmental Responsibility - The company adheres to environmental regulations and has established a comprehensive environmental management system, meeting various national and local standards for wastewater and air emissions[164] - The company obtained an environmental protection administrative permit for wastewater discharge, valid from September 1, 2022, to August 31, 2027[164] - The company has implemented a comprehensive waste gas treatment system to manage emissions from various production processes, ensuring compliance with local environmental standards[169] - The company has established protocols for the management of hazardous waste, ensuring safe handling and disposal in accordance with environmental regulations[170] - The company invested 3.5683 million yuan in environmental governance and protection during the reporting period[174] Community Engagement - The company donated a total of 500,000 RMB worth of materials to the Hai Chen Hope Primary School during the Children's Day event[180] - Cumulative donations reached 690,000 RMB through participation in charity events in Jiangsu Province over the past three years[180] - The company provided over 490,000 RMB in various forms of assistance, benefiting 442 individuals during the reporting period[180]